David R. Amerson

David is the former President (retired 2021), of NeoTract Interventional Urology at Teleflex. He served as President and Chief Executive Officer and member of the Board of Directors for NeoTract, Inc. from July 2011 to October 2017 when the company was successfully acquired by Teleflex for $1.1B. Mr. Amerson led NeoTract to become a best-in-class medical device company, achieving significant milestones including FDA De Novo clearance, new CPT 1 codes, a New Tech APC code and ~300M U.S. covered lives. Both NeoTract and Mr. Amerson have been recognized as one of the most successful Medical Device Companies in recent years. From 2006 to 2011, Mr. Amerson was Global Vice President, General Manager for the Surgical Urology division of Coloplast, a publicly traded medical equipment company based in Denmark. In addition to Palette Life Sciences, he currently serves on the following Boards: Executive Chairman of New Enterprise Associates (NEA) funded company, NC8, Chairman of the Board and Board Member of Calyxo Medical, and Board Member of Relievant Medical. Mr. Amerson holds an MBA from Argosy University and a BA in Political Science from the University of West Georgia.